Goldman Sachs Group Inc. Raises Position in Tyra Biosciences, Inc. $TYRA

Goldman Sachs Group Inc. increased its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 21.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 78,006 shares of the company’s stock after buying an additional 13,896 shares during the quarter. Goldman Sachs Group Inc. owned about 0.15% of Tyra Biosciences worth $725,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of TYRA. US Bancorp DE boosted its stake in shares of Tyra Biosciences by 50.5% during the first quarter. US Bancorp DE now owns 5,435 shares of the company’s stock valued at $51,000 after purchasing an additional 1,823 shares during the period. BNP Paribas Financial Markets bought a new position in Tyra Biosciences in the fourth quarter worth approximately $60,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Tyra Biosciences during the 1st quarter worth $84,000. Exchange Traded Concepts LLC raised its position in Tyra Biosciences by 42.7% during the 1st quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company’s stock valued at $110,000 after purchasing an additional 3,550 shares in the last quarter. Finally, Two Sigma Advisers LP purchased a new stake in shares of Tyra Biosciences in the 4th quarter worth $171,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Price Performance

Shares of TYRA stock opened at $12.73 on Wednesday. The business has a fifty day moving average of $11.52 and a 200 day moving average of $10.33. Tyra Biosciences, Inc. has a 1 year low of $6.42 and a 1 year high of $29.60. The firm has a market capitalization of $678.51 million, a price-to-earnings ratio of -7.15 and a beta of 1.10.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.06. As a group, equities research analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Oppenheimer restated an “outperform” rating and issued a $36.00 price objective on shares of Tyra Biosciences in a report on Wednesday, September 10th. Raymond James Financial started coverage on shares of Tyra Biosciences in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 target price on the stock. Wall Street Zen upgraded shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat.com, Tyra Biosciences currently has a consensus rating of “Buy” and an average target price of $31.86.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.